The Extraordinary General Meeting authorized the Board of Directors to decide, in one or more transactions, on the issuance of shares, and the issuance of options and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Companies Act.
 

The number of shares to be issued based on the authorization may in total amount to a maximum of 180 000 000 shares. The Board of Directors decides on all other terms and conditions of the issuances of shares and options and other special rights entitling to shares. The issuance of shares and options and other special rights entitling to shares may be carried out in deviation from the shareholders' preemptive rights (directed issue) if there is a weighty financial reason for the company. The authorization is valid until 30 June 2025.

For more information, please contact:

Stein Ulve, CEO

Email: stein@eeviahealth.com  
Phone: +358 400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials, with a focus on gut and related health areas, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

As a pioneering company Eevia is developing biomaterials that may have dramatic impact on human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth